行情

FBIO

FBIO

Fortress Biotech
NASDAQ

实时行情|Nasdaq Last Sale

2.830
-0.150
-5.03%
盘后: 2.890 +0.06 +2.12% 16:59 11/26 EST
开盘
2.910
昨收
2.980
最高
2.980
最低
2.805
成交量
44.79万
成交额
--
52周最高
6.10
52周最低
2.360
市值
2.82亿
市盈率(TTM)
-5.9705
分时
5日
1月
3月
1年
5年
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the underwriter of its previously announced ...
GlobeNewswire · 11/17 14:30
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
Zacks.com · 11/15 22:25
Fortress Biotech 每股收益下降 0.15 美元，高于收入
Fortress Biotech (NASDAQ:FBIO): Q3 GAAP EPS of -$0.26 misses by $0.15. Revenue of $21.09M (+122.5% Y/Y) beats by $2.03M. Shares +4.17%. Press Release
Seekingalpha · 11/15 21:46
Fortress Biotech Q3 EPS $0.54 Up From $(0.07) YoY, Sales $21.10M Up From $9.21M YoY
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.54 per share. This is a 871.43 percent increase over losses of $(0.07) per share from the same period last year. The company reported $21.10 million in
Benzinga · 11/15 21:20
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics Avenue Therapeutics is a specialty...
AccessWire · 11/12 15:40
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the closing of its public offering of 1,946,78...
GlobeNewswire · 11/12 14:20
BRIEF-Mustang Bio Reports Q3 Loss Per Share Of $0.19
reuters.com · 11/12 13:14
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologi...
GlobeNewswire · 11/12 13:05
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解FBIO最新的财务预测，通过FBIO每股收益，每股净资产，每股现金流等数据分析Fortress Biotech近期的经营情况，然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测FBIO价格均价为10.17，最高价位24.00，最低价为5.00。
最高24.00
均价10.17
最低5.00
现价2.830
EPS
实际EPS
预期EPS
-0.21-0.16-0.10-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 105
机构持股: 3,143.82万
持股比例: 31.56%
总股本: 9,962.94万
类型机构数股数
增持
28
108.73万
建仓
9
22.26万
减持
22
72.53万
平仓
15
34.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
+0.44%
高管信息
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Executive Director
Michael Weiss
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
FBIO 简况
Fortress Biotech, Inc. (Fortress) 是一家生物制药公司。该公司收购、开发和商业化新型医药和生物技术产品。Fortress通过Fortress及其子公司开发和商业化产品。Fortress拥有11家运营子公司，开展包括 4个处于商业化阶段的项目和25个处于开发阶段的项目，这些项目主要针对6个治疗领域（免疫肿瘤学、血液学、基因治疗、疼痛管理、罕见疾病和皮肤病学）。除了内部开发项目，Fortress还利用其生物制药专业知识和药物开发能力向Fortress的子公司提供帮助，并提供资金和管理服务。Fortress的子公司包括Aevitas Therapeutics、Avenue Therapeutics、Caelum Biosciences、Cellvation, Inc.、Checkpoint Therapeutics、Cyprium Therapeutics、Helocyte, Inc.、Journey Medical Corporation、Mustang Bio、National Holdings Corp和Tamid Bio, Inc.

微牛提供Fortress Biotech Inc(NASDAQ-FBIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的FBIO股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易FBIO股票基本功能。